NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) today announced the release of a white paper titled “StereoCED™ - A Scalable Platform for CNS Drug Delivery,” available in the Scientific Resources section of nmtc1.com. The paper outlines how the company’s StereoCED™ platform is designed to address key barriers to the scalable commercial delivery of brain therapeutics by integrating with existing robotic stereotactic systems in neurosurgical operating rooms.
As advances in cell and gene therapies, biologics, and other central nervous system (CNS) therapeutics drive demand for efficient drug delivery methods, convection-enhanced delivery (CED) has proven effective in bypassing the blood-brain barrier. However, current CED approaches often require lengthy sequential infusions and specialized workflows, which could hinder broader commercial adoption. The StereoCED™ platform is being developed to enable simultaneous, multi-trajectory intracranial drug delivery through a streamlined robotic workflow, potentially reducing procedure time from 8-12 hours to a more manageable duration while maintaining reproducibility and scalability.
“Brain-delivered therapeutics are approaching an important inflection point,” said Dave Rosa, President and Chief Executive Officer of NeuroOne. “As these therapies move toward commercialization, certain intracranial infusion procedures lasting 8 to 12 hours may become a significant bottleneck to commercial adoption. We believe healthcare systems will need solutions that leverage established neurosurgical workflows, significantly reduce procedure time, and support scalable delivery across hospitals. StereoCED™ is being designed with those needs in mind, and we look forward to device availability for research and investigational clinical studies by fiscal year-end.”
The StereoCED™ platform is currently under development and has not been cleared or approved by the U.S. Food and Drug Administration for commercialization. NeuroOne, a medical technology company focused on improving surgical care for neurological disorders, markets a minimally invasive electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. The company is also engaged in research and development for basivertebral nerve ablation and spinal cord stimulation programs.
The release of this white paper comes as the company anticipates making the StereoCED™ platform available for research and investigational clinical studies by the end of its fiscal year. This development could have significant implications for the commercialization of CNS therapeutics, which have historically faced challenges in achieving widespread clinical adoption due to the complexity and time required for drug delivery to the brain.
